Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Todd Neale

November 09, 2022

Presentation AHA 2022

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

Presenter: David E. Kandzari

November 07, 2022

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal Care Resumes

News Daily News

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

Michael O'Riordan

October 18, 2022

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

News Conference News TCT 2022

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

Todd Neale

September 18, 2022

News Opinion CV Team Dispatch

September 2022 News Roundup

L.A. McKeown

September 01, 2022

News Daily News

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Michael O'Riordan

August 18, 2022

Presentation EuroPCR 2022

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Presenter: Felix Mahfoud

May 20, 2022

News Conference News EuroPCR 2022

Registry Data Hint at MACE Benefit With Renal Denervation

Michael O'Riordan

May 17, 2022

Presentation EuroPCR 2022

Patient-Level Pooled Analysis of Ultrasound RDN in RADIANCE-HTN SOLO and TRIO

Presenter: Ajay J. Kirtane, Michel Azizi

May 17, 2022

Presentation ARCH 2022

Current Status and Future of Renal Denervation for Hypertension

Presenter: Tim A. Fischell

April 23, 2022

News Industry News

IMPRESSION Randomized Trial: Past the halfway mark and progressing rapidly

January 22, 2022

News Opinion CV Team Dispatch

January 2022 News Roundup

L.A. McKeown

January 01, 2022

Advertisement

Reduction in BP Drives Treatment Preference for Hypertensive Patients

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Renal Denervation in the Presence of Anti-Hypertensive Medications: Six-Month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN – ON MED Trial

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

September 2022 News Roundup

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Registry Data Hint at MACE Benefit With Renal Denervation

Patient-Level Pooled Analysis of Ultrasound RDN in RADIANCE-HTN SOLO and TRIO

Current Status and Future of Renal Denervation for Hypertension

IMPRESSION Randomized Trial: Past the halfway mark and progressing rapidly

January 2022 News Roundup

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content